» Articles » PMID: 29899374

Role and Prognostic Value of Individual Ambulatory Blood Pressure Components in Chronic Kidney Disease

Overview
Journal J Hum Hypertens
Date 2018 Jun 15
PMID 29899374
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Hypertension is a key risk factor for chronic kidney disease (CKD), but can also be a detrimental consequence of established CKD. Unsurprisingly, the majority of subjects with abnormal creatinine in the general population are also hypertensive, with a huge toll on national health care systems worldwide due to a staggering increase in the risk of cardiovascular complications and end-stage renal disease requiring renal replacement therapy. In this setting, a comprehensive and careful assessment of the whole 24-h blood pressure (BP) profile could be of paramount importance in ensuring a timely diagnosis of hypertension and an optimal therapeutic control. Hence, ambulatory BP monitoring (ABPM) has the potential to become the preferred method for optimal clinical management of CKD patients. ABPM might better define the relationship between BP, target organ damage (TOD), and clinical outcomes. Current evidence suggests that specific day-night BP components, along with average BP values, may have clinical relevance in such patients, despite the suboptimal statistical power of available studies and inconsistencies on the prognostic value of individual BP components. The main aim of our review is to scrutinize the evidence for the usage of ABPM in CKD patients, including the relationship between ambulatory BP recordings and cardiovascular events, and the distinctive features of ABPM in these subjects.

Citing Articles

Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension.

Boutari C, Siskos F Life (Basel). 2023; 13(3).

PMID: 36983961 PMC: 10051756. DOI: 10.3390/life13030806.


Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension.

Angeli F, Verdecchia P, Reboldi G Cardiol Ther. 2021; 10(2):397-406.

PMID: 34251649 PMC: 8555037. DOI: 10.1007/s40119-021-00233-7.


Evaluation of serum free fatty acids in chronic renal failure: evidence from a rare case with undetectable serum free fatty acids and population data.

Liu Z, Hong Q, Peng D, Yang Y, Yu W, Shui H Lipids Health Dis. 2019; 18(1):151.

PMID: 31286991 PMC: 6615299. DOI: 10.1186/s12944-019-1093-5.

References
1.
Mojon A, Ayala D, Pineiro L, Otero A, Crespo J, Moya A . Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int. 2012; 30(1-2):145-58. DOI: 10.3109/07420528.2012.703083. View

2.
Kario K, Shimada K . Risers and extreme-dippers of nocturnal blood pressure in hypertension: antihypertensive strategy for nocturnal blood pressure. Clin Exp Hypertens. 2004; 26(2):177-89. DOI: 10.1081/ceh-120028556. View

3.
Angeli F, Reboldi G, Verdecchia P . Interpretation of ambulatory blood pressure profile: a prognostic approach for clinical practice. J Hypertens. 2015; 33(3):454-7. DOI: 10.1097/HJH.0000000000000497. View

4.
Gentile G, Remuzzi G . Novel Biomarkers for Renal Diseases? None for the Moment (but One). J Biomol Screen. 2016; 21(7):655-70. DOI: 10.1177/1087057116629916. View

5.
Minutolo R, Gabbai F, Borrelli S, Scigliano R, Trucillo P, Baldanza D . Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Am J Kidney Dis. 2007; 50(6):908-17. DOI: 10.1053/j.ajkd.2007.07.020. View